Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Fatigue Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Fatigue Overview | 7 | 1 |
| Fatigue Therapeutics under Development by Companies | 8 | 1 |
| Fatigue Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Fatigue Products under Development by Companies | 12 | 1 |
| Fatigue Companies Involved in Therapeutics Development | 13 | 5 |
| BioLite, Inc. | 13 | 1 |
| Biovista Inc. | 14 | 1 |
| Grifols, S.A. | 15 | 1 |
| Hemispherx Biopharma, Inc. | 16 | 1 |
| MultiCell Technologies, Inc. | 17 | 1 |
| Fatigue Therapeutics Assessment | 18 | 10 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Combination Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 15 |
| (lofepramine hydrochloride + phenylalanine) Drug Profile | 28 | 1 |
| alpha-1 proteinase inhibitor (human) Drug Profile | 29 | 1 |
| BLI-1402 Drug Profile | 30 | 1 |
| Recombinant A1PI Drug Profile | 31 | 2 |
| rintatolimod Drug Profile | 33 | 9 |
| Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis Drug Profile | 42 | 1 |
| Fatigue Dormant Projects | 43 | 1 |
| Fatigue Product Development Milestones | 44 | 10 |
| Featured News &Press Releases | 44 | 1 |
| Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) in Expert Review of Clinical Pharmacology | 44 | 1 |
| Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke | 45 | 1 |
| Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen | 45 | 1 |
| Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study | 46 | 1 |
| Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms | 47 | 1 |
| Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe | 47 | 1 |
| Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations | 48 | 1 |
| May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations | 49 | 1 |
| May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets | 49 | 1 |
| Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference | 50 | 1 |
| Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference | 51 | 1 |
| Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries | 51 | 1 |
| Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen | 51 | 1 |
| Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen | 52 | 1 |
| Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012 | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |